MedTrace Logo

YN001-004 in Patients With Coronary Atherosclerosis in Australia

NCT06700720 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-02-17

No results posted yet for this study

Summary

This study is to evaluate the efficacy and safety of intravenously administered YN001 in patients with coronary atherosclerosis in Australia. This study will be conducted in eligible participants with a diagnosis of coronary atherosclerosis, and at least 1 coronary artery is blocked determined by coronary computed tomography angiography (CCTA)

Conditions

Interventions

DRUG

Dose 1 YN001

Dose 1 YN001 will be administered on Day 1 of each week from Week 1 to Week 13, 13 times in total.

DRUG

Dose 2 YN001

Dose 2 YN001 will be administered on Day 1 of each week from Week 1 to Week 13, 13 times in total.

DRUG

Evolocumab

Evolocumab 140 mg will be administered subcutaneously every 2 weeks.

Sponsors & Collaborators

  • Beijing Inno Medicine Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Teresa Chen, PhD · Beijing Inno Medicine Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-28
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06700720 on ClinicalTrials.gov